Please wait





01/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.


SCHEDULE 13G



 
Dr. Reddy's Laboratories, Inc.
 
Signature:/s/ Stephen Peterson
Name/Title:Vice President, Head of Finance NAG
Date:03/12/2026
 
Dr. Reddy's Laboratories SA
 
Signature:/s/ Sameer Natu
Name/Title:Senior Director - Finance
Date:03/12/2026
 
Dr. Reddy's Laboratories Limited
 
Signature:/s/ K Randhir Singh
Name/Title:Company Secretary and Compliance Officer
Date:03/12/2026